| Title |
A refinement of clinical tumor marker monitoring: Why not use an inverse value of doubling time? / |
| Authors |
Zaleskis, Gintaras ; Bosas, Paulius ; Ulys, Albertas ; Dabkevičienė, Daiva ; Dobrovolskienė, Neringa ; Hudson, Bret Andrew ; Pašukonienė, Vita |
| DOI |
10.1159/000515977 |
| Full Text |
|
| Is Part of |
Medical principles and practice : international journal of the Kuwait University, Health Science Centre.. Basel : Karger. 2021, vol. 30, iss. 3, p. 292-296.. eISSN 1423-0151 |
| Keywords [eng] |
cancer relapse ; prostate cancer ; prostate-specific antigen ; tumor markers |
| Abstract [eng] |
OBJECTIVES: The aim of this study was to compare prostate-specific antigen (PSA) kinetics - half-life time (HT), doubling time (DT), and elimination rate PSA (ePSA) in prostate cancer (PCa) monitoring. Implementation of ePSA in clinical practice could help simplify patient monitoring in the remission phase. MATERIALS AND METHODS: A total of 49 PCa patients were examined by their PSA tests before prostatectomy and after 30 days, 91 days, and 24 months. Conventional PSA rate of change parameters (HT and DT) were compared to a new clinically understandable ePSA parameter. RESULTS: We observed that implementation of inverse value (ePSA) rather than HT or DT has distinct advantages: (1) values are valid when PSA is unchanged (ePSA equals zero), (2) the concept of ePSA can be easily understood, as it is a growth fraction, (3) ePSA fluctuates within a narrow range and is thus easy to interpret, and (4) there are no mathematical flaws (no positive skewing). CONCLUSION: Exploring ePSA norm as ≤0% could help spot biochemical recurrence in a timely manner. Primary health care providers tend to use an irrelevant PSA threshold, that is, 4.0 ng/mL, in postoperative follow-up. The delayed referrals of patients in remission might be reduced if ePSA testing is adopted. |
| Published |
Basel : Karger |
| Type |
Journal article |
| Language |
English |
| Publication date |
2021 |
| CC license |
|
